Skip to main content

Table 1 Characteristics of the included studies

From: Management of allergic rhinitis with leukotriene receptor antagonists versus selective H1-antihistamines: a meta-analysis of current evidence

Author (year)

Country

Design

Patients

Patient number

Mean age (year)

Male (%)

With asthma (%)

LTRAs

SAHs

Concurrent treatment for AR

Duration (weeks)

Outcomes

Meltzer 2000

The US

R, DB

SAR patients aged 15–75 y

187

33.6

44.4

31.1

Montelukast 10 mg/d

Loratadine 10 mg/d

None

2

DNSS, NSS, CSS, DESS, RQLQ

Nayak 2002

The US

R, DB

SAR patients aged 15–82 y

456

36.6

36.7

20.9

Montelukast 10 mg/d

Loratadine 10 mg/d

None

2

DNSS, NSS, CSS, DESS, RQLQ

Philip 2002

The US

R, DB

Non-smoking SAR patients aged 15–81 y

950

36.3

65.5

25.7

Montelukast 10 mg/d

Loratadine 10 mg/d

None

2

DNSS, NSS, CSS, DESS, RQLQ

van Adelsberg 2003a

The US

R, DB

Non-smoking SAR patients aged 15–85 y

693

36.2

40.1

23.4

Montelukast 10 mg/d

Loratadine 10 mg/d

None

2

DNSS, NSS, CSS, DESS, RQLQ

van Adelsberg 2003b

the US

R, DB

SAR patients aged 15–82 y

628

36.3

33.2

22.4

Montelukast 10 mg/d

Loratadine 10 mg/d

None

4

DNSS, NSS, CSS, DESS, RQLQ

Lee 2004

UK

R, DB, CO

Adult PAR patients

12

42

33.3

NR

Montelukast 10 mg/d

Fexofenadine 180 mg/d

None

1

DNSS

Di Lorenzo 2004

Italy

R, DB

SAR patients aged 12–50 y

40

31.8

35

NR

Montelukast 10 mg/d

cetirizine 10 mg/d

Fluticasone propionate aqueous nasal spray

6

DNSS

Hsieh 2004

China

R, DB

Child PAR patients aged 6–12 y

40

8.1

62.5

NR

Montelukast 5 mg/d

Cetirizine 10 mg/d

None

12

DNSS

Ciebiada 2006-levo

Poland

R, DB, CO

Adult PAR patients aged 18–65 y

20

23.7

30

0

Montelukast 10 mg/d

Levocetirizine 5 mg/d

None

6

DNSS, DESS

Ciebiada 2006-deslo

Poland

R, DB, CO

Adult PAR patients aged 18–65 y

20

34.1

20

0

Montelukast 10 mg/d

Desloratadine 5 mg/d

None

6

DNSS, DESS

Jiang 2006

China

R

PAR patients aged 15–65y

63

28.6

41.3

NR

Zafirlukast 40 mg /d

Loratadine 10 mg/d

None

2

DNSS

Philip 2007

the US

R, DB

PAR patients aged 15–85y

752

35.5

33.1

23.7

Montelukast 10 mg/d

Cetirizine 10 mg/d

None

6

DNSS, RQLQ

Lu 2009-1

the US

R, DB

SAR patients aged 15–85 y

228

35.2

36.3

24.1

Montelukast 10 mg/d

Loratadine 10 mg/d

None

2

DNSS, CSS

Lu 2009-2

the US

R, DB

SAR patients aged 15–85 y

267

30.9

38.9

70.8

Montelukast 10 mg/d

Loratadine 10 mg/d

None

2

DNSS, CSS

Liu 2016

China

R

SAR patients aged 16–69 y

64

37.3

54.2

NR

Montelukast 10 mg/d

Fexofenadine 120 mg/d

Nasal budesonide

4

DNSS, RQLQ

Jia 2017

China

R

PAR patients aged 12–56 y

38

29.7

54.4

0

Montelukast 10 mg/d

Loratadine 10 mg/d

Nasal mometasone

4

DNSS

  1. LTRAs leukotriene receptor antagonists, SAHs selective H1-antihistamines, AR allergic rhinitis, US United States, UK United Kingdom, R randomized, DB double blinded, CO crossover, SAR seasonal allergic rhinitis, PAR perennial allergic rhinitis, NR not reported, DNSS daytime nasal symptoms score, NSS nighttime symptoms score, DESS daytime eye symptoms score, CSS composite symptoms score, RQLQ rhinoconjunctivitis quality-of-life questionnaire